Skip to content

Comparison of Proliferative Potential of H-PBSC Based on Demographics and Cryopreservation Time

Comparison of the Proliferative Potential of Human Peripheral Blood Stem Cells Based on Demographic Factors and Cryopreservation Time

Status
UNKNOWN
Phases
Unknown
Study type
Observational
Source
ClinicalTrials.gov
Registry ID
NCT05573412
Enrollment
100
Registered
2022-10-10
Start date
2022-08-16
Completion date
2023-08-16
Last updated
2022-10-10

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Healthy

Brief summary

The goal of this observational study is to observe stored stem cells and determine their capability to grow based on several factors. The main two factors focused on in this study are as follows: * Time stem cells have spent in cryopreservation * Demographic factors (gender, race, age)

Detailed description

This study is a secondary, correlational, single-center laboratory study involving the analysis of previously obtained PBSC samples at the Andrews Research & Education Foundation (AREF). Individuals who previously provided samples for a primary study that has a concluded will be reconsented for this study. No manipulation of samples will occur until Broad Informed Consent has been obtained. Upon Broad Informed Consent being granted, the samples will be removed from cryopreservation and analyzed in a laboratory setting. Each sample's total nucleated cell count (TNC), cell viability, and proliferative potential will be analyzed. Measurements will be performed at different time intervals and the results will be recorded in a password protected system. These parameters will be followed for each available PBSC sample regardless of time spent in cryopreservation to examine if variation in time spent under cryopreservation had an impact on overall cell viability and proliferative potential. Following conclusion of the cell viability data acquisition stage of the study, the data will be further analyzed to determine if there are any statistically relevant correlations between various demographic factors and the viabilities of the PBSC samples. The secondary, demographic factors to be examined include the sample patient's age, sex, and race. The data analysis will determine whether these factors in addition to length of time spent under cryopreservation influenced the PBSC samples' viability and proliferative potential upon the samples being removed from cryopreservation and prepared for analysis.

Interventions

OTHERCellular analysis

Previously cryopreserved samples will be analyzed for total nucleated cell count (TNC), cell viability and proliferative potential

Sponsors

Florida
CollaboratorOTHER
Andrews Research & Education Foundation
Lead SponsorOTHER

Study design

Observational model
OTHER
Time perspective
OTHER

Eligibility

Sex/Gender
ALL
Age
18 Years to No maximum
Healthy volunteers
Yes

Inclusion criteria

* 18 years of age or older * Prior primary study at Andrews Research & Education Foundation must be completed * Additional biospecimens continue to be in a cryopreserved state at Andrews Research & Education Foundation Regenerative Medicine Center (RMC) * Subject is willing and able to provide Broad Informed Consent for secondary study

Exclusion criteria

* Subjects whose biospecimens did not maintain primary study sample labels * Subject is not willing and able to provide Broad Informed Consent for secondary study

Design outcomes

Primary

MeasureTime frameDescription
Beckman-Coulter Flow CytometerAt enrollmentMachine that provides a digital view of cells that are categorized utilizing laser light to differentiate cell types while samples are suspended in a fast-flowing liquid; will be utilized to determine proliferative potential, total nucleated cell count, and cell viability of each cryopreserved sample

Countries

United States

Contacts

Primary ContactJessi Truett
jessica.truett@andrewsref.org8509168570
Backup ContactJoshua Cook, BS
joshua.cook@andrewsref.org8509168590

Outcome results

None listed

Source: ClinicalTrials.gov · Data processed: Feb 4, 2026